Cemiplimab

Generic Name: Cemiplimab

Brand Names: Libtayo

Drug Type: Biotech

Chemical Formula: -

CAS Number: 1801342-60-8

Unique Ingredient Identifier: 6QVL057INT

Background: Cemiplimab is a fully human monoclonal antibody that works against programmed death receptor-1 (PD-1), which is a negative regulator of T cell function. By blocking PD-1, cemiplimab works to enhance T cell-mediated antitumour responses.
...

Indication: Cemiplimab is indicated to treat:

Associated Conditions: Locally Advanced Basal Cell Carcinoma, Locally Advanced Cutaneous Squamous Cell Carcinoma, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Cervical Cancer, Metastatic Non-Small Cell Lung Cancer, Metastatic cutaneous squamous cell carcinoma, Recurrent Cervical Cancer, Metastatic Basal cell carcinoma

Associated Therapies: First Line Chemotherapy

Clinical Trials

ERectile Dysfunctions, gOnadotoxicity and Sexual Health Assessment in Men With Lung Cancer

Recruiting

Conditions: Hypogonadism, Male
NSCLC Stage IV
Sex Disorder
Erectile Dysfunction

Interventions: Drug: Alectinib
Drug: Osimertinib
Drug: Pembrolizumab
Drug: Cemiplimab
Drug: Brigatinib
Drug: Sotorasib
Drug: Lorlatinib 100 mg
Drug: Dabrafenib
Drug: Nivolumab
Drug: Trametinib
Drug: Carboplatin
Drug: Pemetrexed
Drug: Selpercatinib
Drug: Paclitaxel

First Posted Date: 2024-08-01

Last Posted Date: 2024-08-09

Lead Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Target Recruit Count: 80

Registration Number: NCT06532149

Locations: 🇮🇹
Fondazione Policlinico Gemelli IRCCS, Rome, Italy

A Phase II Study of All-Trans Retinoic Acid (ATRA) and Cemiplimab in Patients With Advanced Leiomyosarcoma

Phase 2

Not yet recruiting

Conditions: Leiomyosarcoma
Sarcoma

Interventions: Drug: all-trans retinoic acid
Drug: Cemiplimab
Procedure: Computed Tomography
Procedure: Magnetic resonance imaging

First Posted Date: 2024-07-30

Last Posted Date: 2024-07-30

Lead Sponsor: Gabriel Tinoco

Target Recruit Count: 16

Registration Number: NCT06528769

Locations: 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma

Phase 1

Recruiting

Conditions: Mycosis Fungoides
Anaplastic Large Cell Lymphoma
Relapsed Anaplastic Large Cell Lymphoma
Relapsed Mycosis Fungoides
Peripheral T-Cell Lymphoma, Not Otherwise Specified
Peripheral T Cell Lymphoma
Relapsed Peripheral T-Cell Lymphoma

Interventions: Procedure: Biopsy
Procedure: Biospecimen Collection
Procedure: Bone Marrow Biopsy
Procedure: Computed Tomography
Procedure: Positron Emission Tomography
Biological: Recombinant Vesicular Stomatitis Virus-expressing Human Interferon Beta and Sodium-Iodide Symporter
Procedure: Single Photon Emission Computed Tomography
Biological: Cemiplimab
Biological: Ipilimumab

First Posted Date: 2024-07-18

Last Posted Date: 2024-12-10

Lead Sponsor: Mayo Clinic

Target Recruit Count: 20

Registration Number: NCT06508463

Locations: 🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States

A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancers

Phase 1

Recruiting

Conditions: Primary Peritoneal Carcinoma
Fallopian Tube Cancer
Epithelial Ovarian Cancer

Interventions: Other: 27T51
Drug: Cemiplimab
Drug: Bevacizumab

First Posted Date: 2024-06-21

Last Posted Date: 2024-11-15

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 90

Registration Number: NCT06469281

Locations: 🇺🇸
UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
🇺🇸
John Theurer Cancer Center Hackensack University Medical Center, Hackensack, New Jersey, United States

A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)

Phase 2

Recruiting

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: Cemiplimab
Drug: Platinum-based chemotherapy
Drug: REGN7075

First Posted Date: 2024-06-18

Last Posted Date: 2024-12-09

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 120

Registration Number: NCT06465329

Locations: 🇺🇸
Orchard Healthcare Research Inc., Skokie, Illinois, United States
🇺🇸
Detroit Clinical Research Center, Farmington Hills, Michigan, United States
🇺🇸
University of Tennessee Medical Center, Knoxville, Tennessee, United States

Neoadjuvant Chemo-Immunotherapy and Surgical Resection in Locally Advanced Non-small Cell Lung Cancer With N3 Lymph Node Involvement

Phase 2

Not yet recruiting

Conditions: Non-small Cell Lung Cancer Stage III

Interventions: Drug: Cemiplimab-Rwlc

First Posted Date: 2024-06-10

Last Posted Date: 2024-06-25

Lead Sponsor: Georgetown University

Target Recruit Count: 21

Registration Number: NCT06449313

Locations: 🇺🇸
Lombardi Comprehensive Cancer Center, Georgetown University, Washington, District of Columbia, United States

Cemiplimab and Cetuximab Prior Salvage Surgery in Patients With Recurrent Oral Cavity Squamous Cell Carcinoma (OCSCC).

Phase 2

Recruiting

Conditions: Locally Recurrent Oral Cavity Squamous Cell Carcinoma

Interventions: Drug: Cemiplimab
Drug: Cetuximab

First Posted Date: 2024-06-07

Last Posted Date: 2024-12-18

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 17

Registration Number: NCT06448026

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

Phase II Trial of Ubamatamab Alone or in Combination With Cemiplimab in MUC16-Expressing SMARCB1-Deficient Malignancies

Phase 2

Recruiting

Conditions: SMARCB1-Deficient Malignancies

Interventions: Drug: Ubamatamab
Drug: Cemiplimab

First Posted Date: 2024-06-06

Last Posted Date: 2024-12-18

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 40

Registration Number: NCT06444880

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

Neoadjuvant PD-1 Inhibitor and EGFR Inhibitor in Locally Advanced Cutaneous Squamous Cell Carcinoma

Phase 2

Not yet recruiting

Conditions: Locally Advanced Cutaneous Squamous Cell Carcinoma

Interventions: Drug: Cetuximab
Drug: Cemiplimab

First Posted Date: 2024-05-17

Last Posted Date: 2024-08-29

Lead Sponsor: Melanoma and Skin Cancer Trials Limited

Target Recruit Count: 27

Registration Number: NCT06418724

A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations

Phase 1

Recruiting

Conditions: Metastatic Colorectal Cancer
KRAS G12C Mutations

Interventions: Drug: Cetuximab
Drug: Cemiplimab
Drug: Adagrasib

First Posted Date: 2024-05-14

Last Posted Date: 2024-11-14

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 31

Registration Number: NCT06412198

Locations: 🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy